Visual cycle modulator fails to meet primary endpoint of reducing GA growth rate

Acucela announced that the novel investigational visual cycle modulator emixustat hydrochloride failed to reduce geographic atrophy lesion growth rate in the SEATTLE study, according to a company press release.There was no significant difference in geographic atrophy (GA) lesion growth rate, the primary endpoint of the phase 2b/3 clinical trial, between placebo and any of the three emixustat treatment groups over 2 years, according to the release.